Antifungal prophylaxis in solid organ transplant recipients

References

• Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med. Mycol.45, 305–320 (2007).
   PubMed Web of Science ®Google Scholar
• Singh N. Fungal infections in the recipients of solid organ transplantation. Infect. Dis. Clin. North Am.17, 113–134 (2003).
   PubMed Web of Science ®Google Scholar
• Paya CV. Fungal infections in solid-organ transplantation. Clin. Infect. Dis.16, 677–688 (1993).
   PubMed Web of Science ®Google Scholar
• Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect. Dis. Clin. North Am.9, 1045–1074 (1995).
   PubMedGoogle Scholar
• Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis.50, 1101–1111 (2010).
   PubMed Web of Science ®Google Scholar
• Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am. J. Transplant.8, 426–431 (2008).
   PubMed Web of Science ®Google Scholar
• Imataki O, Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematologic malignancies. Support Care Cancer DOI: 10.1007/s00520-010-0998-3 (2010) (Epub ahead of print).
   Google Scholar
• Kusne S, Torre-Cisneros J, Manez R et al. Factors associated with invasive lung aspergillosis and significance of positive cultures after liver transplantation. J. Infect. Dis.166, 1379–1383 (1992).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine78, 123–138 (1999).
   PubMed Web of Science ®Google Scholar
• Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis.36, 46–52 (2003).
   PubMed Web of Science ®Google Scholar
• Husain S, Tollemar J, Dominguez EA et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation75, 2023–2029 (2003).
   PubMed Web of Science ®Google Scholar
• Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation73, 63–67 (2002).
   PubMed Web of Science ®Google Scholar
• Collins LA, Samore MH, Roberts MS et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J. Infect. Dis.170, 644–652 (1994).
   PubMed Web of Science ®Google Scholar
• Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis.36, 46–52 (2003).
   PubMed Web of Science ®Google Scholar
• Patel R, Portela D, Badley A et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation62, 926–934 (1996).
   PubMed Web of Science ®Google Scholar
• Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology21, 1328–1336 (1995).
   PubMed Web of Science ®Google Scholar
• Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins L, Lewis WD. Fungal infections complicating orthotopic liver transplantation. Trans. Am. Clin. Climatol. Assoc.106, 38–48 (1995).
   PubMedGoogle Scholar
• Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect. Transplant.14, 375–382 (1995).
   Google Scholar
• Tollemar J, Höckerstedt K, Ericzon BG, Jalanko H, Ringdén O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation59, 45–50 (1995).
   PubMed Web of Science ®Google Scholar
• Lorf T, Braun F, Rüchel R, Müller A, Sattler B, Ringe B. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses42, 47–53 (1999).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.131, 729–737 (1999).
   PubMed Web of Science ®Google Scholar
• Lumbreras C, Cuervas-Mons V, Jara P et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J. Infect. Dis.174, 583–588 (1996).
   PubMedGoogle Scholar
• Biancofiore G, Bindi ML, Baldassarri R et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl. Int.15, 341–347 (2002).
   PubMed Web of Science ®Google Scholar
• Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, Colby WD. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation76, 977–983 (2003).
   PubMedGoogle Scholar
• Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation74, 688–695 (2002).
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation71, 910–913 (2001).
   PubMedGoogle Scholar
• Pappas PG, Andes D, Schuster M et al. Invasive fungal infections in low-risk liver transplant recipients: a multicenter prospective observational study. Am. J. Transplant.6, 386–391 (2006).
   PubMed Web of Science ®Google Scholar
• Hadley S, Huckabee C, Pappas PG et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl. Infect. Dis.11, 40–48 (2009).
   PubMed Web of Science ®Google Scholar
• Castroagudin JF, Ponton C, Bustamante M et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Tranplant. Proc.37, 3965–3967 (2005).
   PubMedGoogle Scholar
• Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis.25, 549–561 (2006).
   PubMedGoogle Scholar
• Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl.12, 850–858 (2006).
   PubMed Web of Science ®Google Scholar
• Fortún J, Martín-Dávila P, Montejo M et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation87, 424–435 (2009).
   PubMed Web of Science ®Google Scholar
• Kubak BM. Fungal infection in lung transplantation. Transpl. Infect. Dis.4, 24–31 (2002).
   PubMedGoogle Scholar
• Baddley JB, Andes DR, Marr KA et al. Factors associated with mortality in transplant patients with invasive Aspergillosis. Clin. Infect. Dis.50, 1559–1567 (2010).
   PubMed Web of Science ®Google Scholar
• Minari A, Husni R, Avery RK et al. The incidence of invasive Aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl. Infect. Dis.4, 195–200 (2002).
   PubMedGoogle Scholar
• Sole A, Morant P, Salavert M et al. Aspergillus fumigatus in lung transplant recipients: risk factors and outcome. Clin. Microbiol. Infect.11, 359–365 (2005).
   PubMed Web of Science ®Google Scholar
• Valentine VG, Gupta MR, Walker JE et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J. Heart Lung Transplant.28, 163–169 (2009).
   PubMed Web of Science ®Google Scholar
• Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and immunosuppressants. Pharmacotherapy26, 1730–1744 (2006).
   PubMed Web of Science ®Google Scholar
• Westney GE, Kesten S, Hoyos A et al. Aspergillus infection in single and double lung transplant recipients. Transplantation61, 915–919 (1996).
   PubMed Web of Science ®Google Scholar
• Husni RN, Gordon SM, Longworth DL et al. Cytomegalovirus infection is a risk factor for invasive Aspergillosis in lung transplant recipients. Clin. Infect. Dis.26, 753–755 (1998).
   PubMed Web of Science ®Google Scholar
• Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med. Mycol.45, 305–320 (2007).
   PubMed Web of Science ®Google Scholar
• Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am. J. Transplant.9, S180–S191 (2009).
   PubMed Web of Science ®Google Scholar
• Dummer JS, Lazariashvilli N, Barnes J et al. A survey of anti-fungal management in lung transplantation. J. Heart Lung Transplant.23, 1376–1381 (2003).
   Google Scholar
• Husain S, Zaldonis D, Kusne S et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl. Infect. Dis.8, 213–218 (2006).
   PubMedGoogle Scholar
• Borro JM, Sole A, de la Torre M et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant. Proc.40, 3090–3093 (2008).
   PubMedGoogle Scholar
• Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant.6, 3008–3016 (2006).
   PubMed Web of Science ®Google Scholar
• Erjavec Z, Woolthuis GM, de Vries-Hospers HG et al. Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary Aspergillosis in haematological patients. Eur. J. Clin. Microbiol. Infect. Dis.16, 364–368 (1997).
   PubMed Web of Science ®Google Scholar
• Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: a study of risk factors. J. Heart Lung Transplant.20, 1274–1281 (2001).
   PubMed Web of Science ®Google Scholar
• Drew RH, Ashley EA, Benjamin DK et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung transplant recipients. Transplantation77, 232–237 (2004).
   PubMed Web of Science ®Google Scholar
• Reichenspurner H, Gamberg P, Nitschke M et al. Significant reduction in the number of fungal infections after lung-, heart–lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant. Proc.29, 627–628 (1997).
   PubMed Web of Science ®Google Scholar
• Muñoz P, Rodríguez C, Bouza E et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am. J. Transplant.4, 636–643 (2004).
   PubMed Web of Science ®Google Scholar
• Albano L, Bretagne S, Mamzer-Bruneel MF. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin. Infect. Dis.48, 194–202 (2009).
   PubMed Web of Science ®Google Scholar
• Panackal AA, Dahlman A, Keil KT et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation75, 1050–1053 (2003).
   PubMedGoogle Scholar
• Benedetti E, Gruessner AC, Troppmann C et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J. Am. Coll. Surg.183, 307–316 (1996).
   PubMedGoogle Scholar
• Humar A, Kandaswamy R, Granger D, Gruessner RW, Gruessner AC, Sutherland DE. Decreased surgical risks of pancreas transplantation in the modern era. Ann. Surg.231, 269–275 (2000).
   PubMedGoogle Scholar
• Guaraldi G, Cocchi S, Codeluppi M. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation80, 1742–1748 (2005).
   PubMed Web of Science ®Google Scholar
• Akamatsu N, Sugawara Y, Kaneko J et al. Preemptive treatment of fungal infection based on plasma (1→3) β-D-glucan levels after liver transplantation. Infection35, 346–351 (2007).
   PubMed Web of Science ®Google Scholar
• Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. Clin. Microbiol. Infect.15, 93–97 (2009).
   PubMed Web of Science ®Google Scholar
• Singh N. Antifungal prophylaxis in solid organ transplant recipients: considerations for clinical trial design. Clin. Infect. Dis.39, S200–S206 (2004).
   Google Scholar
• Vehreschild JJ, Rüping MJ, Wisplinghoff H et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J. Antimicrob. Chemother.65, 1466–1471 (2010).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med.356, 335–347 (2007).
   PubMed Web of Science ®Google Scholar
• Sánchez-Ortega I, Patiño B, Arnan M et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant. DOI: 10.1038/bmt.2010.185 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Alexander BD, Perfect JR, Daly JS et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation86, 791–796 (2008).
   PubMed Web of Science ®Google Scholar